Clinical Trial

Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT

Name: Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT — clinical trial record (NCT07675174)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies undergoing an RIC allogeneic PBSC transplant from a 5/6 or 6/6 sibling or 7/8 or 8/8 matched unrelated donor.

Trial Details

NCT Number	NCT07675174
Lead Sponsor	Northwell Health
Conditions	GVHD - Graft-Versus-Host Disease
Enrollment	72 participants
Start Date	2026-07-01
Primary Completion	2030-07-01 (estimated)
Study Completion	2032-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-30